Join the club for FREE to access the whole archive and other member benefits.

Longevity Biotech

Company that develops a new class of therapeutics via artificial protein technology.

Longevity Biotech is developing a new class of therapeutic candidates called Hybridtides®. Our focus is on delivering clinically transformative products that tackle the most challenging aspects of medicine today. The unique Hybridtide® scaffold provides critical enhancements over previous peptide development efforts.

Longevity Biotech has assembled a team of worldwide experts in leading peptide drug development programs. Our growing management team along with our advisors have deep and broad expertise in bringing new biological products into and through clinical trials.

Visit website:




Details last updated 09-Nov-2020

People at Longevity Biotech

Scott Shandler

Founder and CEO at Longevity Biotech.

Longevity Biotech News

Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Topics mentioned on this page:
Laboratory Automation